Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Shimpei YamashitaShuzo HamamotoJunya FurukawaKazutoshi FujitaMasayuki TakahashiMakito MiyakeNoriyuki ItoHideto IwamotoYasuo KohjimotoIsao HaraPublished in: Japanese journal of clinical oncology (2024)
High pre-treatment LIPI is suggested by our results to be a significant independent predictor of poor prognosis in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma.